> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# PMV Pharmaceuticals' Cancer Pill Delivers 48% Response Rate In Previously Treated Ovarian Cancer Patients
- URL: https://www.bullished.co/pmv-pharmaceuticals-cancer-pill-delivers-48-response-rate-in-previously-treated-ovarian-ac16b82d/
- Published: 2026-11-20T21:21:40.000Z
- Updated: 2026-11-20T21:21:40.000Z
- Description: Responses lasted a median of 10.4 months in the primary analysis; PMV expects to seek accelerated FDA approval in early 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, PMVP, Industry: Healthcare

[PMV Pharmaceuticals](https://www.bullished.co/tag/pmvp/), which develops cancer drugs targeting the tumor-suppressor protein p53, reported a [48% confirmed response](https://www.globenewswire.com/news-release/2026/11/20/3407616/0/en/pmv-pharmaceuticals-announces-promising-updated-data-from-the-pynnacle-phase-2-pivotal-trial-of-rezatapopt-monotherapy-in-patients-with-tp53-y220c-mutated-advanced-solid-tumors.html?ref=bullished.co) rate Friday for its experimental pill rezatapopt in previously treated ovarian cancer patients. Responses lasted a median of 10.4 months in the primary analysis, and the company expects to apply for accelerated FDA approval in the first quarter of 2027.

## 31 Responses In The Primary Group

Investigators recorded tumor responses in 31 of [65 patients](https://finance.yahoo.com/healthcare/articles/pmv-pharmaceuticals-announces-promising-updated-153000151.html?ref=bullished.co) whose cancers carried the TP53 Y220C mutation and resisted platinum chemotherapy or failed to respond to it. One patient had a complete response and 30 had partial responses; the disease-control rate was 83%.

The results came from the mid-stage portion of PMV's PYNNACLE trial, which tested rezatapopt alone without a comparison group. The analysis used data collected through September 4, 2026, across approximately 70 trial sites.

Alison M. Schram, a medical oncologist at Memorial Sloan Kettering Cancer Center and a study investigator, presented the results Friday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. “Patients with platinum-resistant ovarian cancer who have progressed on standard therapies have few treatment options,” Schram said.

## A Broader Test Across Tumors

Across all tumor groups, the response rate was 36% among 168 evaluable patients. That tally included four complete responses, 53 confirmed partial responses and four unconfirmed partial responses. The median time to response was 1.3 months, and responses lasted a median of 8.1 months.

The broader ovarian-cancer group had a 45% response rate among [101 patients](https://finance.yahoo.com/healthcare/articles/pmv-pharmaceuticals-announces-promising-updated-153000151.html?ref=bullished.co), including four unconfirmed partial responses. Confirmed response rates were 21% in lung cancer, 17% in breast cancer, 45% in endometrial cancer and 21% in the other-solid-tumor group.

Patients across the trial had received a median of three previous systemic treatments. In the ovarian group, that median was four; 93% had high-grade serous ovarian cancer and 97% had platinum-resistant or refractory disease.

The safety analysis covered [180 patients](https://www.globenewswire.com/news-release/2026/11/20/3407616/0/en/pmv-pharmaceuticals-announces-promising-updated-data-from-the-pynnacle-phase-2-pivotal-trial-of-rezatapopt-monotherapy-in-patients-with-tp53-y220c-mutated-advanced-solid-tumors.html?ref=bullished.co), including 113 with ovarian cancer. Treatment-related side effects caused 11 patients, or 6%, to stop treatment, including seven ovarian-cancer patients. Most treatment-related side effects were mild or moderate; frequent effects included nausea, fatigue, vomiting, anemia and changes in kidney and liver blood tests.

## An Approval Bid For Its Lead Pill

Rezatapopt is designed to restore p53's tumor-suppressing function when the protein carries the Y220C mutation. PMV has no approved products to sell and owns worldwide commercial rights to its programs, including other early-stage p53 drug candidates.

The FDA previously granted rezatapopt Fast Track designation for locally advanced or metastatic solid tumors carrying the p53 Y220C mutation. It also received orphan-drug designation for TP53 Y220C-positive ovarian, fallopian tube and primary peritoneal cancers.

Deepika Jalota, PMV's chief development officer, described the potential treatment as a once-daily pill patients could take at home without chemotherapy. “We expect to submit our NDA for accelerated approval in the first quarter of 2027,” Jalota said, referring to the company's planned FDA approval application.

PMV's planned application targets platinum-resistant or refractory ovarian cancer, the population at the center of the primary analysis.

Learn

- [Item 8.01: other events →](https://www.bullished.co/learn/8-k-items-explained/#item-801-other-events)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — PMV Pharmaceuticals, Inc. (PMVP)](https://www.sec.gov/Archives/edgar/data/0001699382/000119312526470247/d169492d8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d169492dex991.htm — PMV Pharmaceuticals, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001699382/000119312526470247/d169492dex991.htm?ref=bullished.co) — SEC EDGAR
- [PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors](https://finance.yahoo.com/healthcare/articles/pmv-pharmaceuticals-announces-promising-updated-153000151.html?ref=bullished.co) — Yahoo Finance
- [PMV Pharmaceuticals Announces Promising Updated Data From](https://www.globenewswire.com/news-release/2026/11/20/3407616/0/en/pmv-pharmaceuticals-announces-promising-updated-data-from-the-pynnacle-phase-2-pivotal-trial-of-rezatapopt-monotherapy-in-patients-with-tp53-y220c-mutated-advanced-solid-tumors.html?ref=bullished.co) — globenewswire.com

### More on PMV Pharmaceuticals

- [PMV Pharmaceuticals Completes $50 Million Offering, Extending Expected Funding Into 2028](https://www.bullished.co/pmv-pharmaceuticals-completes-50-million-offering-extending-expected-funding-into-2028-35076502/)
- [PMV Pharmaceuticals Names Biotech Investor Matt Eckler To Board As It Readies Ovarian Cancer Drug Filing](https://www.bullished.co/pmv-pharmaceuticals-names-biotech-investor-matt-eckler-to-board-as-it-readies-ovarian-b8c6025c/)

[All PMV Pharmaceuticals (PMVP) coverage →](https://www.bullished.co/tag/pmvp/)